FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

Inclusion Criteria

• •Part 1 - Eligibility Criteria for Neoadjuvant Chemotherapy
• •Patients must have histologically confirmed invasive cervical cancer with adenocarcinoma, adenosquamous or squamous histology and FIGO 2018 IB2 measuring \>2 cm - ≤4 cm by radiological imaging (MRI).
• •Patients must be premenopausal and wish to preserve fertility.
• •At time of registration, patient may not have had any prior therapy to treat their cancer lesion.
• •Eastern Cooperative Group (ECOG) performance status ≤ 2.
• •Within 7 days of the proposed start of treatment, patients must have normal organ and marrow function.
• •No evidence of active uncontrolled infection (patients on antibiotics are eligible).
• •Patient must have disease that is measurable per the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
• •Ability to understand and willing to sign a written informed consent document.
• •Patients must agree to use effective contraceptive methods prior to study entry, during study participation, and for at least one year after the fertility-sparing surgery (FSS) procedure. A serum pregnancy test within 72 hours prior to study registration is required.
• •Part 2 - Eligibility Criteria for Fertility Sparing Surgery (FSS)
• •Completed 3 cycles of neo-adjuvant chemotherapy and achieved a complete response (CR) or partial response (PR) with reduction of the lesion to \<2 cm on physical examination and MRI.